THY1 and neoplasm: By using an immunodeficient Rag−/− mouse model, it has been shown that NKp46−CD4−ILC3 accumulation leads to IL-17 and IL-22 production, which promotes tumor development, whereas depletion of ILCs with anti-Thy1 mAbs limits tumor growth in colon cancer (141).